Postpartum Low Libido: How to Stop Treatment Safely and What to Expect

What Is Actually Happening to Your Libido After Birth

Low libido in the postpartum period is not a character flaw or a sign that something is permanently broken. The physiology is direct: delivery causes an abrupt withdrawal of placental estrogen and progesterone, and if you are breastfeeding, prolactin suppresses hypothalamic GnRH pulsatility, which drives estrogen to near-menopausal levels and testosterone below your pre-pregnancy baseline.

One prospective cohort study published in the Journal of Sexual Medicine found that sexual function scores, including desire, arousal, and satisfaction, declined significantly across all domains in the first three months postpartum compared with pre-pregnancy values, with the slowest recovery in breastfeeding women. This is not surprising given the hormonal milieu those women are operating in.

The Hormonal Cascade You Are Living Through

After delivery, estradiol drops from pregnancy peaks of 15,000-40,000 pg/mL to levels below 20 pg/mL within days. Prolactin, which can remain elevated throughout exclusive breastfeeding, suppresses ovarian function and with it the follicular estrogen production that normally supports genital blood flow, lubrication, and central desire pathways. Free testosterone, already lower in pregnancy, falls further in lactating women compared with non-lactating controls.

Sleep matters enormously here. Fragmented sleep disrupts hypothalamic-pituitary-adrenal axis regulation, raises cortisol, and independently reduces sexual desire through its effects on mood and energy. No hormonal treatment fully compensates for profound sleep deprivation.

What "Normal" Recovery Looks Like

For non-breastfeeding women, ovarian function typically resumes within 4-8 weeks postpartum, and estrogen recovers with it. ACOG guidance on postpartum care recognizes that sexual health concerns, including desire changes, are a routine part of the fourth-trimester visit and should be addressed proactively rather than waiting for a woman to raise them.

For breastfeeding women, low libido may persist for as long as nursing continues. That is a physiological state, not a disorder requiring treatment, though it may warrant treatment if it causes personal distress or relationship strain.

Who Actually Needs Treatment (and Who Probably Does Not)

Low libido after birth becomes a clinical diagnosis, hypoactive sexual desire disorder (HSDD), only when it causes personal distress. ACOG's clinical guidance and The Menopause Society's position statement on female sexual dysfunction both emphasize the distress criterion. If you have low desire and you are not distressed by it, you do not have HSDD, and treatment is not indicated.

Life-Stage Framing: Postpartum vs. Perimenopause

Postpartum low libido is physiologically distinct from the low libido that develops during perimenopause, and this distinction matters for both diagnosis and treatment decisions. In perimenopause, estrogen decline is gradual and permanent without hormone therapy. In the postpartum period, the hormonal disruption is time-limited in most cases. Treatments appropriate in one context may not fit the other.

A woman in her late 30s experiencing postpartum low libido who also notices irregular cycles, hot flashes, and mood swings before weaning should prompt her provider to check an FSH and estradiol, as early perimenopause can co-occur with the postpartum period, though this is uncommon.

The Conditions That Amplify Postpartum Low Libido

Several conditions common in women of reproductive age worsen postpartum sexual desire:

• Postpartum depression (PPD): Affects up to 15% of new mothers. CDC surveillance data shows PPD rates are highest in the first three months postpartum. Depression itself reduces libido, and many antidepressants (SSRIs in particular) further suppress desire as a side effect.
• Postpartum thyroiditis: Occurs in roughly 5-10% of women, typically 1-6 months after delivery. Hypothyroid states reduce sexual desire. Screening with TSH is warranted if libido loss is accompanied by fatigue, weight changes, or hair loss disproportionate to what is expected.
• Pelvic floor dysfunction and dyspareunia: Pain with intercourse is not low libido, but it creates avoidance behavior that is difficult to distinguish clinically without careful questioning. Episiotomy sites, perineal tears, and vaginal dryness from hypoestrogenism all contribute.
• PCOS: Women with PCOS may have had androgen excess before pregnancy. The postpartum period can unmask or shift the hormonal picture, and some will have lower testosterone than expected once the pregnancy-driven androgen boost resolves.

What Treatments Are Used and What Each Involves

Before discussing how to stop treatment, it helps to be precise about what is being stopped. Postpartum low libido management spans several categories.

Vaginal Estrogen

Vaginal estrogen (estradiol cream, ring, or tablet; or prasterone/DHEA intravaginally) addresses the local hypoestrogenism that causes dryness, thinning, and dyspareunia. It does not reliably raise systemic estrogen or directly treat central desire pathways, but treating dyspareunia reliably improves desire in women whose low libido is driven by pain-avoidance.

A Cochrane review of vaginal estrogen for genitourinary symptoms confirms efficacy for dryness and dyspareunia with minimal systemic absorption at standard doses, which is relevant to breastfeeding safety (discussed below).

Testosterone (Off-Label)

Systemic testosterone is not FDA-approved for any indication in women in the United States. The Menopause Society's 2023 position statement on testosterone therapy supports its use at physiological doses for HSDD in postmenopausal women, with extrapolated use in premenopausal women acknowledged as off-label and under-studied. Postpartum use is even more scantly studied, and any prescription in a breastfeeding woman requires careful risk-benefit discussion.

Bupropion and Buspirone

Both are used off-label for HSDD. Bupropion has the most trial evidence among non-hormonal options. A randomized controlled trial by Segraves et al. demonstrated bupropion SR improved desire scores compared with placebo in premenopausal women with HSDD. Buspirone has anxiolytic properties that may benefit women whose low libido is driven by performance anxiety or relationship stress.

Psychosexual Therapy

Cognitive behavioral therapy (CBT) and couples-based sex therapy address the psychological and relational dimensions of postpartum libido loss. A systematic review in the Journal of Sex and Marital Therapy found that CBT-based interventions improved desire and satisfaction scores in women with HSDD, though most trials excluded women in the early postpartum period specifically.

Stopping Treatment Safely: A Framework by Treatment Type

The approach to stopping treatment depends on what you are taking, how long you have been taking it, whether you are still breastfeeding, and whether the underlying physiological driver (lactational hypoestrogenism, PPD, thyroid dysfunction) has resolved.

Stopping Vaginal Estrogen

Vaginal estrogen does not require a taper. You can stop at any time. Symptoms of dryness and dyspareunia may return, often within a few weeks, if the underlying hypoestrogenism is still present. The decision to stop should be based on whether you are still symptomatic, not on an arbitrary time limit.

If you stop because you have weaned and your menstrual cycle has returned, estrogen production should restore vaginal tissue health within 1-3 cycles. If symptoms persist after two full cycles, re-evaluate with your provider rather than assuming they will resolve on their own.

Stopping Testosterone

Because postpartum testosterone prescribing is off-label and doses vary, stopping should be done with your prescriber's guidance. There is no established taper protocol for physiological-dose testosterone in women. Abrupt stopping does not produce a physiological withdrawal syndrome, but you should expect that any libido benefit may take 4-8 weeks to fade, given testosterone's tissue-level effects.

If you are breastfeeding and started testosterone, stopping immediately is the right move if your infant's pediatrician raises any concerns, or if you become pregnant again. The Endocrine Society's clinical practice guideline on androgen therapy in women does not address postpartum or lactating women specifically, which is an explicit evidence gap in this area.

Stopping Bupropion

Bupropion requires a gradual taper to minimize discontinuation effects, even though it is not classified as an antidepressant with significant withdrawal risk in the same way SSRIs are. Common practice is to reduce the dose by 50% for 1-2 weeks before stopping entirely. If you were taking bupropion primarily for HSDD rather than for depression or smoking cessation, and your desire has returned naturally, discuss a taper timeline with your prescriber.

Bupropion does transfer into breast milk. A pharmacokinetic study measured infant exposure at approximately 2% of the maternal weight-adjusted dose via breast milk, which most lactation specialists consider low, though the active metabolite hydroxybupropion also transfers and has a longer half-life. Any decision to continue or stop bupropion while breastfeeding should involve your prescriber and ideally a lactation medicine specialist.

Stopping Buspirone

Buspirone does not produce the dependence or withdrawal associated with benzodiazepines, but stopping abruptly after extended use can cause rebound anxiety in some women. A two-week taper is reasonable. Its specific lactation data are limited; LactMed (NIH) lists buspirone as having limited data in lactation and recommends caution.

Stopping Psychosexual Therapy

Therapy does not have a pharmacological stop date. The usual practice is to complete a defined course (typically 8-16 sessions for CBT-based models), consolidate skills, and transition to as-needed or maintenance sessions. There is no safety concern with stopping, though many women find a planned final session more useful than simply not booking the next appointment.

Pregnancy, Lactation, and Contraception: What You Must Know

This section is required reading if you are using any treatment for postpartum low libido and are sexually active.

Breastfeeding Safety by Treatment

Vaginal estrogen: At standard low doses, systemic absorption is minimal, and most major lactation resources including LactMed consider low-dose vaginal estrogen compatible with breastfeeding. High-dose vaginal preparations or systemic estrogen may reduce milk supply by suppressing prolactin, so these are generally avoided in women who want to continue nursing.

Testosterone: There is no established safe dose of exogenous testosterone during breastfeeding. Testosterone can be aromatized to estradiol, which may suppress lactation, and androgen exposure to the infant through breast milk is poorly characterized. The conservative recommendation is to avoid systemic testosterone while breastfeeding unless the benefit clearly outweighs the risk and the prescriber and patient have explicitly discussed the unknowns.

Bupropion: Transfers into breast milk with approximately 2% relative infant dose; use with monitoring is accepted by many clinicians. The American Academy of Pediatrics classifies it as a drug for which the effect on nursing infants is unknown but may be of concern.

Buspirone: Limited data. Caution is advised.

Contraception: Do Not Assume Breastfeeding Protects You

The lactational amenorrhea method (LAM) provides roughly 98% protection against pregnancy when you are exclusively breastfeeding, your baby is under six months old, and your period has not returned. ACOG Practice Bulletin on Contraception confirms these three criteria must all be met for LAM to be effective.

Once any of these changes, you need another method. Estrogen-containing contraceptives reduce milk supply and are generally deferred until six weeks postpartum or later in non-breastfeeding women and until weaning in breastfeeding women. Progestin-only methods (mini-pill, depot medroxyprogesterone, hormonal IUD) do not impair lactation and are appropriate immediately postpartum.

If your libido is returning and you are becoming sexually active again, revisiting contraception with your provider is not optional. An unintended pregnancy within twelve months of delivery carries its own maternal and infant health risks.

Who This Is Right for and Who Should Wait

Women for Whom Active Treatment Makes Sense

Treatment for postpartum low libido is most appropriate when distress is significant, the cause is identifiable, and the underlying physiology is unlikely to resolve on its own within a reasonable timeframe. Specifically:

• Breastfeeding women at 6 or more months postpartum who have severe dyspareunia and vaginal atrophy. Low-dose vaginal estrogen is appropriate and supported by evidence.
• Women with confirmed PPD whose antidepressant is causing sexual side effects. Switching to or augmenting with bupropion, with guidance from a psychiatrist, is a reasonable strategy.
• Women with hypothyroidism confirmed by TSH. Optimizing levothyroxine dose should precede any libido-specific treatment.
• Women who have weaned but whose desire has not recovered by 4-6 months post-weaning, particularly if they are approaching perimenopause.

Women Who Should Wait and Watch

• Women less than three months postpartum who are not breastfeeding. Hormonal recovery is likely still underway.
• Exclusively breastfeeding women who have low desire but no distress and no dyspareunia. This is physiological, not pathological.
• Women whose main issue is exhaustion and relationship disconnection. A sleep intervention or couples counseling may deliver more than a prescription.

Signs That Recovery Is Happening (and When to Seek Re-Evaluation)

Recovery from postpartum low libido is rarely linear. Most women notice gradual improvement in desire as sleep consolidates, breastfeeding frequency decreases, and ovarian function recovers. Concrete signs that things are moving in the right direction include the return of spontaneous sexual thoughts, increased genital sensitivity, improved natural lubrication, and less pain with intercourse.

Seek re-evaluation if:

• You weaned six or more months ago and desire has not returned at all
• You have resumed regular cycles but still have vaginal atrophy and dryness
• Your mood, energy, and libido are all significantly impaired, suggesting an undiagnosed thyroid or mood disorder
• You are having pain with intercourse that is not improving with vaginal moisturizers and low-dose vaginal estrogen after 8-12 weeks of consistent use

The International Society for the Study of Women's Sexual Health (ISSWSH) position statement recommends a structured biopsychosocial evaluation for any woman with persistent HSDD, including history of trauma, relationship factors, and hormonal status, before escalating treatment or assuming a treatment failure.

A Note on the Evidence Gap

Women in the early postpartum period are almost universally excluded from clinical trials of sexual dysfunction treatments. The FDA guidance on evaluating female sexual dysfunction acknowledges that HSDD trials have historically enrolled primarily postmenopausal women, leaving a significant extrapolation gap for reproductive-age and postpartum women. Most dosing recommendations, efficacy estimates, and side-effect profiles used in postpartum clinical practice are borrowed from perimenopausal or non-pregnant premenopausal populations.

This is not a reason to withhold treatment from women who need it. It is a reason to be transparent: your provider is using clinical judgment informed by indirect evidence when managing postpartum low libido with any pharmacological agent.